Kornimate/medical-research-clean huggingface dataset:
efficacy of vortioxetine on cognitive dysfunction in patients with partial or full remission of major depressive disorder

Conditions: Major Depressive Disorder

Summary: to assess the efficacy of vortioxetine (10 to 20 mg/day) as adjunctive treatment to stable selective serotonin reuptake inhibitor (ssri) dose versus stable ssri monotherapy on cognitive performance (focusing on the aspect concerning speed of processing, executive functioning and attention) in patients who are in partial or full remission from their major depressive episode (mde).


Eligibility criteria:
inclusion criteria: * the patient has achieved either partial (some symptoms of a mde are present but full criteria are not met) or full remission of major depressive disorder (mdd), diagnosed according to dsm-iv-tr™. * the patient has hamd-17 total score ≤10. * the patient has received ssri monotherapy for the mde from which the patient is currently in full or partial remission for ≥12 weeks at licensed doses and been on stable dose ≥8 weeks prior to screening visit. * the patient has ≥50% response to current ssri treatment (antidepressant treatment response questionnaire \[atrq\]). * the patient has a pdq-d total score \>25. * the patient is a man or woman, aged ≥18 and ≤65 years. exclusion criteria: * the patient has a score ≥70 on the dsst (numbers of correct symbols) at the baseline visit. * the patient is, in the opinion of the investigator, not able to complete the neuropsychological tests validly at the baseline visit. * the patient has physical, cognitive, or language impairment of such severity as to adversely affect the validity of the data derived from the neuropsychological tests. * the patient is diagnosed with reading disability (dyslexia). * the patient has a history of lack of response to previous adequate treatment with vortioxetine. * the patient has any current psychiatric disorder or axis i disorder (according to dsm-iv-tr™ criteria) other than mdd, as assessed using mini international neuropsychiatric interview (mini). * the patient has a current or has had a diagnosis of dysthymic disorder within 3 months preceding the onset of the depressive episode from which the patient is currently in full or partial remission (dsm-iv-tr™ criteria). * the patient has borderline, schizotypal, schizoid, paranoid, histrionic, antisocial personality disorders (axis ii) as comorbid or primary diagnosis (dsm-iv-tr™ criteria). * the patient suffers from personality disorders, mental retardation, pervasive development disorder, attention-deficit/hyperactivity disorder, organic mental disorders, or mental disorders due to a general medical condition (dsm-iv-tr™ criteria). * the patient has a current diagnosis or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features (dsm-iv-tr™ criteria). other protocol-defined inclusion and exclusion criteria may apply.
effect of probiotics on chronic periodontitis in smoker and non- smokers

Conditions: Chronic Periodontitis

Summary: periodontitis is one of the most common chronic inflammatory disease with the etiology of bacterial plaque and is associated with a number of putative bacterial species. the periodontal destruction is substantially mediated by the host, driven by the bacterial challenge. the presence of pathogenic bacteria with the absence of so-called "beneficial bacteria" and the susceptibility of the host are the main aetiological factors of periodontal diseases.


Eligibility criteria:
inclusion criteria: * patients free from any systemic illness * previously untreated moderate to severe generalised chronic periodontitis. * patients free from adverse reactions to lactose or fermented milk products * patient unwilling to quit smoking and smokers over the past one year ( smoker arm). exclusion criteria: * previous history of antibiotic usage over past 6 months * patients who are eligible for antibiotic usage during the treatment course * patients who are pregnant, lactating, alcoholic or who had undergone any surgical or nonsurgical therapy within 6 months. * acute oral lesions or necrotising ulcerative periodontitis
association between dose dialysis by kt and mortality

Conditions: End Stage Renal Disease; Hemodialysis Patients

Summary: the aim of this study is to assess whether patients receiving current recommendations of an adequate dialysis dose by kt adjusted for body surface area improved survival at 24 months compared to those who do not get it, as well as assess whether patients receiving a dose greater obtain more benefit.


Eligibility criteria:
inclusion criteria: * \> 18 years old * \> six months on hemodialysis * receiving 3 sessions of dialysis per week * having 5 or more valid measures of kt during the month exclusion criteria: * active chronic inflammatory diseases * liver cirrhosis * neoplasms * chronic immunosuppression or use of anti-inflammatory
estimating the short-term effectiveness of online advertisements for improving health

Conditions: Anorexia; Obesity; Smoking Cessation

Summary: bing ads designed to encourage people to adopt healthier practices (e.g., stop smoking, become physically active, stop consuming harmful content) are shown using the advertising system, to test which ads are more effective as apparent in the subsequent queries to bing submitted by users who saw the ads.


Eligibility criteria:
inclusion criteria: * use of the bing ad system with target phrases. exclusion criteria: * none
the effect of aerobic exercise on genetic molecules

Conditions: Diabetes Mellitus, Type 2; Aerobic Exercise; Genetic Response

Summary: the aim of this study is to compare the effects of high intensity interval exercise and moderate intensity continuous exercise on some genetic molecules in patients with type 2 diabetes mellitus.

volunteers with type 2 diabetes mellitus will be evaluated in terms of any contra-indication that will restrain them from making exercise. 90 male or female volunteers who are suitable in terms of inclusion/exclusion criteria will be invited for the study. volunteers will be randomly distributed to one of the 3 groups. each group will contain 30 participants. 1. group will make aerobic exercise which is in the form of high intensity interval exercise 2.group will make aerobic exercise which is in the form of moderate intensity continuous exercise 3. control group. exercise groups will be cycling under observation in the hospital setting. control group will make simple stretching exercises at home. participants will be requested to complete a 3 months of exercise. they will be evaluated before and at the end of the 3 months of exercise with blood tests to measure genetic molecules related with metabolism.

Eligibility criteria:
inclusion criteria: clinica diagnosis of type 2 diabetes mellitus less than 10 years and more than 1 year. * must have appropriate medical therapy and diet. * must not be treated with insulin. * must be exercising less than 210 minutes/ week exclusion criteria: * prominent cardiovascular disease * coronary artery disease * moderate to severe valvular disease * atrial fibrillation * untreated hypertension * congenital heart disease * retinopathy * neuropathy * macro albuminuria * cerebrovascular disease * ejection fraction less than 40 * body mass index greater than 35. * prominent ischemic changes in ekg at rest or during exercise. * cigarette or alcohol addiction * on drugs that interferes with body fat distribution (such as insulin, thiazolidinediones

Keywords: type 2 diabetes mellitus exercise aerobic
data base project for acquisition of cancer patient data in practices and ambulant therapy

Conditions: Carcinoma

Summary: the purpose of this registry is to evaluate the situation regarding ambulant therapy of cancer patients in different practices in germany. it should provide insight into the implementation of schemes for cancer therapy predefined in the guidelines, the treatment of diverse adverse reactions and the counter measures taken. thereby, potential differences in treatment and with that differences in quality amongst individual practices might be identified. the medium to long term aim is to contribute to positively influence the quality of medical care of cancer patients in germany.


Eligibility criteria:
inclusion criteria: * 18 years and older * tumor disease (carcinoma of either breast, ovary, lung, colon, stomach, pancreas, rectum or plasmacytoma) * written informed consent exclusion criteria: none

Keywords: breast cancer ovarian cancer lung cancer colon cancer gastric cancer pancreatic cancer rectum cancer plasmacytoma
arb and ccb longest combination treatment on ambulatory and home bp in hypertension with atrial fibrillation -multicenter study on time of dosing (acrobat)

Conditions: Hypertension and Atrial Fibrillation

Summary: evaluation of 24-hour antihypertensive effect of long-acting arb-ccb tablet administrated to hypertensive patients with atrial fibrillation, and comparison of 24-hour antihypertensive effect of long-acting arb-ccb tablet between morning administration and bedtime administration.


Eligibility criteria:
inclusion criteria: 1. hypertensive patients who meet the following conditions: patients who meet any of the following standards of blood pressure after administration of 40 mg/day telmisartan or 5 mg/day amlodipine for 4 weeks: - blood pressure at hospital visit: systolic blood pressure is 140 mmhg or higher, and/or diastolic blood pressure is 90 mmhg or higher. (average of 3 measurements obtained at a scheduled visit) - blood pressure at home: systolic blood pressure is 135 mmhg or higher, and/or diastolic blood pressure is 85 mmhg or higher. (average of measurements for the 5 days prior to drug assignment \[4 measurements per day in total: 2 in the morning and 2 before bedtime\]) 2. patients with atrial fibrillation detected on an electrocardiogram within the last 2 years prior to obtaining informed consent. 3. age: 20 years old or older (at time of informed consent) 4. sex: male or female 5. clinical classification: outpatient 6. patients who give written consent of agreement to voluntarily participate in the clinical study. exclusion criteria: 1. patients with serious liver and/or kidney disease 2. patients with history of allergy to telmisartan or amlodipine 3. patients receiving antihypertensives other than telmisartan or amlodipine during observation period 4. patients diagnosed with persistent atrial fibrillation or chronic (permanent) atrial fibrillation. 5. patients with atrial fibrillation caused by irreversible illness (e.g., heart surgery, pulmonary embolism, or hyperthyroidism) 6. patients with average systolic blood pressure at hospital visit higher than 180 mmhg during observation period. 7. patients with new york heart association (nyha) class iii-iv heart failure, patients with heart failure requiring hospitalization, or patients with poor left ventricular function. 8. patients who have stroke or cardiac infarction within 6 months before giving consent. 9. patients planning to undergo pulmonary artery ablation surgery or any surgical procedure (including pci). 10. patients who are breast-feeding, pregnant, possibly pregnant, or plan to become pregnant. 11. in addition, patients who are determined as not eligible by their study doctor.
denosumab fracture intervention randomized placebo controlled trial in japanese patients with osteoporosis

Conditions: Osteoporosis

Summary: evaluate the efficacy and safety of denosumab in the treatment of involutional (postmenopausal and senile) osteoporotic subjects with prevalent fragility vertebral fracture(s)


Eligibility criteria:
inclusion criteria: * involutional (postmenopausal and senile) osteoporosis with prevalent fragility vertebral fractures exclusion criteria: * any underlying condition,(other than bmd) that might have resulted in abnormal bone metabolism
the effects of smell on mood and physical responses

Conditions: Stress; Anxiety; Depression

Summary: the purpose of this study is to examine the body's response to relaxing and stimulating fragrances commonly used in aromatherapy.

despite aromatherapy's popularity, efficacy data are scant, and potential mechanisms are controversial. this randomized controlled trial examined the psychological, autonomic, endocrine, and immune consequences of one purported relaxant odor (lavender), one stimulant odor (lemon), and a no-odor control (water), before and after a stressor (cold pressor); 56 healthy men and women were exposed to each of the odors during three separate visits. to assess the effects of expectancies, participants randomized to the "blind" condition were given no information about the odors they would smell; "primed" individuals were told what odors they would smell during the session, and what changes to expect. experimenters were blind. in each case we measured several different aspects of the cellular immune response, as well as skin barrier repair following tape stripping. this design allowed us to examine the ability of the odors to modulate endocrine and immune function, and health-relevant cutaneous responses.

Eligibility criteria:
inclusion criteria: * healthy adults with a normal sense of smell exclusion criteria: * treatment with medication that has immunological or endocrinological consequences * chronic health problems that affect immune or endocrine systems * allergy to perfume or cosmetics * problems with sense of smell * respiratory problems * smoker * current active asthma * use of psychoactive drugs or mood-altering medication * history of anxiety disorder, major depression, bipolar disorder, schizophrenia, or other psychotic disorders * history of chest pain or ventricular fibrillation

Keywords: aromatherapy smell
electromyographic biofeedback on performance of vastus medialis oblique muscle in knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: this study intends to determine the effects of electromyographic biofeedback on performance of vastus medialis oblique muscle in knee osteoarthritis.

this is a single blinded randomized controlled trial, will be conducted at railway general hospital.rawalpindi. (emg) biofeedback as an adjunct therapy to standard exercise regime for increasing muscle strength ,this study is planned to determine the effects of electromyographic biofeedback on performance and thickness of vastus medialis oblique muscle, knee pain and on lower extremity function in patients with knee osteoarthritis. the sample size was calculated to be n=34 through open epi tool version 3, with 95 % confidence interval (ci), and power 80%. after the completion of therapeutic protocols, the participants will be assessed with the help of numeric pain rating scale (nprs), womac, lequesne questionnaire , 1 repetition maximum( rm) and with msk ultrasound

Eligibility criteria:
inclusion criteria: * age : in between 45 - 65years * both genders * subjects with a definite diagnosis of knee oa according to the guidelines of the american college of rheumatology with at least 6 months of knee pain. * grade 1 or 2 joint cartilage degradation based on the kellgren-lawrence classification * body mass index (bmi) of \<35 kg/m2 exclusion criteria: * subjects who had undergone physical therapy or intraarticular injection in the past 3 months * patients who had taken oral corticosteroids in the past 4 weeks * patients with a history of surgical interventions on their knees * subjects with a history of radiculopathy, or those with a history of systemic diseases, such as rheumatoid arthritis
evaluation and training of muscle fitness in pre-frail individuals

Conditions: Fatigue

Summary: muscle strength and endurance are important indexes of fitness. the muscle strength is the most important single predict factor of functional ability in aged frail individuals. frailty related muscle weakness and fatigue are adapted from the pre-frail stage. finding the contributions of the central and the peripheral factors to the deficits of muscle fitness and developing an effective muscle fitness training program for pre-frail individuals are very important. the muscle weakness and fatigue can be categorized into peripheral or central causes. the central fatigue and voluntary activation failure originate from the decrease in motivation or the reduction of the conduction within corticospinal tracts. long term activation failure and central fatigue will cause disuse of muscle and result in peripheral weakness and peripheral fatigue. studies found the selective type ii fiber atrophy in aged people and this finding was different from the type i atrophy in conventional immobilization models. it is possible that the activation failure leads to the recruitment failure of high threshold type ii fibers at the pre-frail stage. quantifying the weighting of central versus peripheral factors contributing to the exercise limitation in pre-frail people is important. most of the conventional strength and endurance training programs are based on the researches of young groups. these programs are not able to prevent people become frail. it is possibly that, due to the limitation of central fatigue, the pre-frail individuals stop exercise before the effective intensity being achieved. almost no training program has been design for enhancing the voluntary activation level and relief the central fatigue. seeking an appropriate training program to enhance central activation at the pre-frail stage is very important for preventing people become frail. previous studies have shown that increasing afferent input by peripheral electrical stimulation (es) at sensory threshold enhanced the plasticity of contralateral primary sensory cortex, the excitability of corticospinal tracts, and the functional performance in young adults. es, which is easy to quantify the dose of afferent input, is a feasible method to be used in training. combining afferent input with strength training might be able to overcome the central activation failure and help recruit high threshold motor unit in pre-frail individuals.


Eligibility criteria:
health subjects: exclusion criteria: musculoskeletal injuries for knee. osteoporosis. diabetes.

Keywords: fatigue aging transcranial magnetic stimulation interpolated twitch technique
spect-ct vs mri for the diagnosis of osteoarthritis in the foot and ankle

Conditions: Osteoarthritis Ankle; Osteoarthritis

Summary: the diagnose of symptomatic osteoarthritis in the ankle, mid- and hind foot remains challenging. there is no gold standard for the work-up and various hospitals use different protocols. current literature shows a promising role for spect-ct imaging in ankle, hind- and midfoot oa. in a previous study investigating the role of spect-ct in a reproducible group we have observed a change in diagnosis in 53% when spect-ct data was added to the data of conventional workup alone. in 26% of patients addition of spect-ct data resulted in change of the original treatment plan. to our knowledge no prospective studies are available on this subject for both spect-ct and mri. in our clinic both spect-ct and mri are used in the work-up for patients with ankle, hind- and midfoot pain. although we experience good result with spect-ct, mri might be able to detect symptomatic oa as well. moreover mri provide more information about soft tissue and is less harmful for the patient in comparison to spect-ct. the aim of this study is to determine the diagnostic performance of spect-ct and mri when used routinely in patients with symptomatic oa of the ankle, hind- and midfoot.

objective: the objective is to determine diagnostic performance of spect-ct and mri when used routinely in patients with symptomatic oa of the ankle, hind- and midfoot. study design: prospective cohort study. study population: all patients ≥18years old, referred to the martini hospital groningen department of orthopedic surgery with suspected symptomatic osteoarthritis of the foot and ankle and rest pain of nrs ≥4. main study parameters/endpoints: main parameters will be the diagnostic performance (a.o. sensitivity and specificity, positive and negative predictive value)of spect-ct and mri. the standard work up consist of questionnaires, detailed physical examination, conventional radiographic, mri, spect-ct imaging and ultrasound guided injections. there are no additional risks for participating in this study compared to current standardised hospital workup.

Eligibility criteria:
inclusion criteria: * suspected symptomatic ankle, hind- or midfoot oa * informed consent * age ≥ 18 years * average nrs ≥4 over the past week. exclusion criteria: * contraindication for surgery * contraindication for spect-ct or mri * contraindication for intra-articular injections * isolated forefoot pathology * fracture, ligamentous or tendon injury of the ankle, hind- and/or midfoot trauma within one year before presentation * history of neurological disease * history of foot and/or ankle surgery (affected side) * inability to read and understand the written information

Keywords: spect/ct mri osteoarthritis foot and/or ankle
efficacy and safety of high-dose ivermectin for reducing malaria transmission: a dose finding study

Conditions: Malaria

Summary: in western kenya the prevalence of malaria in \<5 year olds has fallen from 70% in 1997 to 40% in 2008, where it has now stagnated. innovative approaches are needed to continue towards elimination. ivermectin is a broad spectrum antiparasitic endectocide widely used for the control of onchocerciasis and lymphatic filariasis at a dose of 150-200 mcg/kg. ivermectin at this dose has a potent, but short-lived effect for 6-11 days on mosquito survival, egg-laying, and parasite sporogony. higher doses are needed to prolong its mosquitocidal effects. previous studies have shown ivermectin is very well tolerated and safe even up to 2,000 mcg/kg. this dose finding study will evaluate the transmission blocking effect of high-dose ivermectin to define the optimal dose for future use of ivermectin in combination with artemisinin-based combination therapy (act) for mass drug administration (mda). it explores a research question of global relevance. a prolonged transmission blocking effect of ivermectin could have substantial consequences for malaria control in the next decades. the results are expected to inform national malaria control programs in malaria endemic countries, to inform who guidelines, and to contribute to the regulatory process.


Eligibility criteria:
inclusion criteria: * symptomatic, uncomplicated plasmodium falciparum infection * positive malaria microscopy or malaria rdt (pldh) * age: 18-50 years * provide written informed consent * agree to be able to travel to clinic on days: 1, 2, 7, 10, 14, 21, and 28 exclusion criteria: * signs or symptoms of severe malaria * unable to provide written informed consent * for women: pregnancy or lactation * hypersensitivity to ivermectin or dp * qtc \>460 ms on ecg * body mass index (bmi) below 16 or above 32 kg/m2 * haemoglobin concentration below 9 g/dl * taken ivermectin in the last month * taken dihydroartemisinin-piperaquine in the last 12 weeks * loa loa as assessed by travel history to angola, cameroon, chad, central african republic, congo, dr congo, equatorial guinea, ethiopia, gabon, nigeria and sudan * history and/or symptoms indicating chronic illness * current use of tuberculosis or anti-retroviral medication * previously enrolled in the same study

Keywords: malaria plasmodium dihydroartemisinin-piperaquine ivermectin